KA/EN
Register
Medicines reference
Search
Search
Active substance

Gentamicin

Favourites

Aminoglycoside. Registered in Georgia: 2 veterinary products and 1 human medicine. Forms: ear drops, eye drops.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Gentamicin
Dose Species Indication Route Frequency Source
1–2 drops Dog, Cat Maintenance Into the eye every 3-8 hours
Source: EMA UPD SPC 2023
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
GENTAMICIN WZF 0.3% - VET 3 mg/ml eye drops, solution - SPC (Poland)
EU Union Product Database, 2023
Before use

Safety information

Known Contraindications

  • Critical
    Do not use if hypersensitive to gentamicin or other aminoglycosides.
    Sources: UK SPC
Latin name
Gentamicin
Georgian name
გენტამიცინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
3 of 3 forms
Products
Easotic, Gentocil, Otibiovin
Human medicines in Georgia
Gentocil
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
All forms and registration3

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Easotic, Ear drops

hydrocortisone aceponate 1.11 mg/ml + miconazole 15.1 mg/ml + gentamicin 1505 IU/ml, ear drops, suspension for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Easotic

hydrocortisone aceponate 1.11 mg/ml + miconazole 15.1 mg/ml + gentamicin 1505 IU/ml, ear drops, suspension for dogs
Assessed clinical scopeDog · Labelled topical treatment of susceptible mixed bacterial and fungal otitis externa in dogs after otoscopy and ear cleaning · Into the ear
Care settingVeterinary-diagnosed outpatient otitis treatment
vetman score 7.8/10 Good
Evidence confidence: High Georgia: Yes, veterinary · Verified on 18 Oct 2026

A practical, evidence-supported short-course option for correctly diagnosed susceptible canine otitis externa; never use through a perforated tympanum.

Regulatory and scientific credibility8.5/10

The exact three-component ear suspension has a current September 2026 UK SPC and active Georgian veterinary registration, plus comparative clinical trial evidence.

Clinical efficacy8.0/10

The corticosteroid-antifungal-aminoglycoside combination addresses inflammation and susceptible mixed infection, with controlled trial support; cytology and response should determine antimicrobial fit.

Safety and tolerability6.5/10

An intact tympanum is mandatory because gentamicin is potentially ototoxic; hypersensitivity, generalised demodicosis and concurrent ototoxic treatment are hard restrictions.

Clinical practicality8.5/10

One calibrated pump per affected ear once daily for five days is simple and short, provided the canal is first cleaned, dried and examined.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Never use with a perforated tympanum; examine the ear before treatment.
  • Do not combine with other ototoxic substances or use in generalised demodicosis.
  • Use cytology and clinical response to confirm that a gentamicin-miconazole combination is justified.
Assessment sources
  1. VMD SPC 20262026
  2. Canine otitis RCT 20182018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Hydrocortisone aceponate1.11 mg/ml Miconazole15.1 mg/ml Gentamicin1505 IU/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Virbac · France
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ეასოტიკი®
Verified on: 18 Oct 2026
 EU Yes, veterinary
№ EU/2/08/085
Verified on: 18 Oct 2026
 UK Yes, veterinary
№ Vm 05653/5002
Verified on: 18 Oct 2026
 US Yes, veterinary
№ NADA 141-330
Verified on: 18 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026

Gentocil 3 mg/ml, Eye drops

gentamicin, eye drops 5 ml, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label topical treatment of diagnosed susceptible superficial bacterial ocular infection in dogs, excluding progressive/deep/intraocular disease
5.6/10
Weak evidence support
vetman assessment

Gentocil

3 mg/ml, gentamicin, eye drops 5 ml, human medicine
Assessed clinical scopeDog · Off-label topical treatment of diagnosed susceptible superficial bacterial ocular infection in dogs, excluding progressive/deep/intraocular disease · Into the eye
Care settingVeterinarian-selected treatment after complete ocular examination, fluorescein staining and organism assessment, with instructed home application and an early planned recheck
vetman score 5.6/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-018410 · Verified on 22 Oct 2026 Off-label use

A transparent but off-label human formulation with credible gentamicin activity for selected susceptible superficial canine infection. Product-specific preservative/phosphate risks and the absent veterinary regimen keep it below a situational choice; progressive ulcer disease needs urgent broader care.

Regulatory and scientific credibility6.0/10

Exact current composition, 5 ml presentation and 28-day in-use life are transparent, with current Georgian and Portuguese human registrations. Same-strength EU and FDA veterinary controls support plausibility, but Gentocil itself has no dog/cat authorisation or product-specific veterinary dossier.

Clinical efficacy6.5/10

Same-strength veterinary labels and FDA approval establish gentamicin activity for susceptible superficial dog ocular infection. Canine keratitis series show useful but population- and organism-dependent susceptibility: gentamicin may cover Pseudomonas yet fail beta-haemolytic Streptococcus, and severe progressive ulcers often need culture-led combination and procedural care.

Safety and tolerability5.0/10

Topical systemic exposure is low, but exact Gentocil contains 0.01% benzalkonium chloride and phosphate buffers with explicit damaged-corneal-surface irritation and rare severe-corneal-calcification warnings. Epithelial defect, pain, allergy and resistant bacterial/fungal superinfection are reported; safety depends on corneal diagnosis, limited exposure and early reassessment.

Clinical practicality4.5/10

A sterile ready-to-use 5 ml dropper and 28-day in-use life are familiar, but no exact veterinary Gentocil regimen exists. Painful-eye restraint, potentially frequent dosing, multiple-drop sequencing, contamination control and rapid recheck can be substantial; severe disease cannot be managed as routine home monotherapy.

Full-course cost-effectiveness-

Current Georgian full-course price and an exact veterinary Gentocil regimen were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this score covers only diagnosed susceptible superficial bacterial ocular infection. It does not score every human-label indication, prophylaxis, an undiagnosed red eye or non-bacterial conjunctivitis/keratitis.
  • Human ophthalmic product; all dog/cat use is off-label. Exact Gentocil contains gentamicin 3 mg/ml, benzalkonium chloride 0.1 mg/ml and phosphate buffers. Do not transfer this score to another gentamicin strength, preservative system, ointment, ear or injectable product.
  • Complete ocular examination and fluorescein staining are mandatory. Stromal infiltrate or malacia, deep ulcer, descemetocele, perforation, marked uveitis, glaucoma, vision loss or suspected intraocular infection requires urgent ophthalmic escalation—not routine home monotherapy.
  • Use cytology and culture/susceptibility for ulcerative, severe, progressive, previously treated, recurrent or poorly responsive disease. Gentamicin coverage is organism- and region-dependent; do not assume that a listed spectrum proves susceptibility.
  • Formulation-specific corneal warning: 0.01% benzalkonium chloride may irritate or injure a dry/damaged epithelial surface, and phosphate can rarely calcify a severely damaged cornea. Reconsider frequent exposure or choose an appropriate preservative-free/alternative formulation when the surface is compromised.
  • Stop and reassess transient burning that persists, increasing pain, redness, tearing, photophobia, opacity, discharge, pruritus, blurred/altered vision, epithelial defect, hypersensitivity or bacterial/fungal superinfection. Do not mask deterioration by simply increasing frequency.
  • No exact Gentocil dog/cat regimen is established. The human schedule, Gentamicin WZF veterinary schedule and FDA comparator schedule are not interchangeable defaults; frequency and duration require an individual prescription and early response review.
  • Ophthalmic surface use only: never inject subconjunctivally or into the globe. Separate concurrent eye drops as instructed, apply ointment last, and verify compatibility rather than mixing medicines in the bottle or on the dropper.
  • Pregnancy/lactation: exact dog/cat reproductive safety is not established. Use only after veterinary benefit–risk assessment; reduce nasolacrimal/systemic exposure where clinically appropriate and prevent licking of overflow.
  • Wash hands, do not touch the sterile tip to eye, lashes, skin or fingers, recap immediately and never share between patients. Store at or below 25°C, record opening date and discard 28 days after first opening.
Assessment sources
  1. Gentocil exact leaflet2025
  2. Gentocil GE register2026
  3. Gentocil Portugal audit2026
  4. UPD SPC 20232023
  5. FDA veterinary control2015
  6. Tiacil VMD control2023
  7. BAC corneal toxicity2010
  8. UK canine keratitis2023
  9. Canine keratitis Australia2016
  10. Canine ulcer isolates US2020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label topical treatment of diagnosed susceptible superficial bacterial ocular infection in cats, excluding viral/chlamydial and progressive/deep/intraocular disease
5.5/10
Weak evidence support
vetman assessment

Gentocil

3 mg/ml, gentamicin, eye drops 5 ml, human medicine
Assessed clinical scopeCat · Off-label topical treatment of diagnosed susceptible superficial bacterial ocular infection in cats, excluding viral/chlamydial and progressive/deep/intraocular disease · Into the eye
Care settingVeterinarian-selected treatment after complete ocular examination, fluorescein staining and organism assessment, with instructed home application and an early planned recheck
vetman score 5.5/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-018410 · Verified on 22 Oct 2026 Off-label use

A transparent off-label formulation with useful feline gentamicin susceptibility evidence, but not a default for the feline red eye. FHV/Chlamydia differentials, difficult repeated dosing, corneal-relevant excipients and no exact cat regimen keep its value weak and diagnosis-dependent.

Regulatory and scientific credibility6.0/10

Exact current composition, 5 ml presentation and 28-day in-use life are transparent, with current Georgian and Portuguese human registrations. Same-strength EU and FDA veterinary controls support plausibility, but Gentocil itself has no dog/cat authorisation or product-specific veterinary dossier.

Clinical efficacy6.5/10

Same-strength veterinary labels/FDA approval include cats, and a culture-confirmed feline keratitis series found 89% overall gentamicin susceptibility. That is meaningful but in-vitro/class evidence, not an exact Gentocil outcome, and it does not justify treating common feline viral or chlamydial disease as bacterial.

Safety and tolerability5.0/10

Topical systemic exposure is low, but exact Gentocil contains 0.01% benzalkonium chloride and phosphate buffers with explicit damaged-corneal-surface irritation and rare severe-corneal-calcification warnings. Epithelial defect, pain, allergy and resistant bacterial/fungal superinfection are reported; safety depends on corneal diagnosis, limited exposure and early reassessment.

Clinical practicality4.0/10

The ready 5 ml dropper is simple, but feline restraint, dropper avoidance and potentially frequent dosing are often difficult, while no exact Gentocil cat regimen exists. Diagnostic separation from FHV/Chlamydia, product sequencing, contamination control and rapid recheck add clinically necessary burden.

Full-course cost-effectiveness-

Current Georgian full-course price and an exact veterinary Gentocil regimen were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this score covers only diagnosed susceptible superficial bacterial ocular infection. It does not score every human-label indication, prophylaxis, an undiagnosed red eye or non-bacterial conjunctivitis/keratitis.
  • Human ophthalmic product; all dog/cat use is off-label. Exact Gentocil contains gentamicin 3 mg/ml, benzalkonium chloride 0.1 mg/ml and phosphate buffers. Do not transfer this score to another gentamicin strength, preservative system, ointment, ear or injectable product.
  • Complete ocular examination and fluorescein staining are mandatory. Stromal infiltrate or malacia, deep ulcer, descemetocele, perforation, marked uveitis, glaucoma, vision loss or suspected intraocular infection requires urgent ophthalmic escalation—not routine home monotherapy.
  • Use cytology and culture/susceptibility for ulcerative, severe, progressive, previously treated, recurrent or poorly responsive disease. Gentamicin coverage is organism- and region-dependent; do not assume that a listed spectrum proves susceptibility.
  • Formulation-specific corneal warning: 0.01% benzalkonium chloride may irritate or injure a dry/damaged epithelial surface, and phosphate can rarely calcify a severely damaged cornea. Reconsider frequent exposure or choose an appropriate preservative-free/alternative formulation when the surface is compromised.
  • Stop and reassess transient burning that persists, increasing pain, redness, tearing, photophobia, opacity, discharge, pruritus, blurred/altered vision, epithelial defect, hypersensitivity or bacterial/fungal superinfection. Do not mask deterioration by simply increasing frequency.
  • No exact Gentocil dog/cat regimen is established. The human schedule, Gentamicin WZF veterinary schedule and FDA comparator schedule are not interchangeable defaults; frequency and duration require an individual prescription and early response review.
  • Ophthalmic surface use only: never inject subconjunctivally or into the globe. Separate concurrent eye drops as instructed, apply ointment last, and verify compatibility rather than mixing medicines in the bottle or on the dropper.
  • Pregnancy/lactation: exact dog/cat reproductive safety is not established. Use only after veterinary benefit–risk assessment; reduce nasolacrimal/systemic exposure where clinically appropriate and prevent licking of overflow.
  • Wash hands, do not touch the sterile tip to eye, lashes, skin or fingers, recap immediately and never share between patients. Store at or below 25°C, record opening date and discard 28 days after first opening.
Assessment sources
  1. Gentocil exact leaflet2025
  2. Gentocil GE register2026
  3. Gentocil Portugal audit2026
  4. UPD SPC 20232023
  5. FDA veterinary control2015
  6. Tiacil VMD control2023
  7. BAC corneal toxicity2010
  8. Feline bacterial keratitis study2020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Gentamicin3 mg/ml
Formulation Type
Eye drops
Administration route
Into the eye
Registration
Georgia Yes, human
Human (Ministry of Health, RAMA)
In the register: გენტოცილი 3 მგ/მლ თვალის წვეთები 5 მლ
№ რ-018410
Verified on: 22 Oct 2026
 EU Yes, human
№ PT 9624304
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Dog/cat use is off-label. A matching-strength, matching-form FDA veterinary comparator supports 1–2 drops in the affected eye(s) 2–4 times daily for diagnosed susceptible bacterial conjunctivitis. Duration is diagnosis- and response-dependent; reassess early. Do not use for deep, melting, perforated or intraocular disease.

Otibiovin, Ear drops

triamcinolone acetonide 0.5 mg + salicylic acid 5 mg + gentamicin sulfate 2 mg + carbethopendecinium bromide 0.125 mg per ml, ear drops
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant treatment of severe canine external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management
6.0/10
Situational / acceptable
vetman assessment

Otibiovin

triamcinolone acetonide 0.5 mg + salicylic acid 5 mg + gentamicin sulfate 2 mg + carbethopendecinium bromide 0.125 mg per ml, ear drops
Assessed clinical scopeDog · Label-concordant treatment of severe canine external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management · Into the ear
Care settingVeterinary otoscopy and cytology before cleaning, intact-tympanum confirmation, susceptibility-led selection for severe/recurrent infection, instructed high-frequency home treatment and planned clinical/cytological recheck
vetman score 6.0/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A transparent authorised option for a narrow, diagnosed susceptible canine otitis role, but not an empirical all-purpose ear drop: intact tympanum, susceptibility, primary-cause treatment and demanding frequent dosing determine value.

Regulatory and scientific credibility7.5/10

The exact dog/cat formulation, dose, strict indication restriction and 12-day open life are transparent, with current Georgian and Czech/EU authorisation. The regulator document is old and no independent exact-product trial or broad pharmacovigilance record was identified.

Clinical efficacy6.0/10

Gentamicin, anti-inflammatory triamcinolone, salicylic acid and cationic antiseptic are mechanistically coherent for selected susceptible otitis. Historical isolates showed 90% overall and 85% Pseudomonas gentamicin susceptibility, not universal coverage; no exact-product trial and no conventional dedicated antifungal limit confidence.

Safety and tolerability5.5/10

An intact tympanum materially reduces risk, and the exact label reports no known adverse effects, but topical gentamicin remains potentially ototoxic. Steroid masking/immunosuppression, irritation from salicylic acid/ethanol/antiseptic, low systemic antibiotic exposure and a painful diseased canal require active monitoring.

Clinical practicality4.5/10

Four to five drops three to four times daily, then two to three times daily, plus cleaning/massage for up to 12 days is measurable but demanding for home adherence. Pain, canal stenosis, resistant infection and frequent handling may make treatment unreliable without demonstration and early recheck.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Hard stop: confirm an intact tympanic membrane before use. Do not use with rupture or when middle-ear exposure cannot be responsibly excluded. Gentamicin may be ototoxic, especially beyond an abnormal tympanum.
  • Obtain cytology before cleaning and diagnose the primary cause. The exact label restricts use to serious infection supported by pathogen identification, susceptibility to the active and resistance to common antibiotics; do not use as an empirical all-purpose ear drop.
  • Dose is 4–5 drops into the affected external canal 3–4 times daily initially, then 2–3 times daily after three days; massage gently. Usual duration is 5–7 days and the absolute label maximum is 12 days.
  • Recheck clinically and cytologically. Stop and urgently assess new hearing loss, head tilt, nystagmus, ataxia, vertigo, facial-nerve change, marked pain or worsening discharge; investigate otitis media rather than continuing blindly.
  • Gentamicin susceptibility is not universal and historical Pseudomonas coverage was about 85%. Culture/susceptibility is especially important for rods, severe/recurrent disease, prior antimicrobial exposure or poor response; minimise resistance selection.
  • No conventional dedicated antifungal or acaricide is present. Treat confirmed yeast/fungal disease and Otodectes with an appropriate effective plan; in-vitro gentamicin inhibition of Malassezia is not clinical antifungal equivalence.
  • Triamcinolone can reduce inflammation and pain but can mask progression, delay healing, promote secondary infection and cause local/systemic glucocorticoid effects. Do not extend beyond 12 days or repeat courses without re-diagnosis.
  • Salicylic acid, ethanol and carbethopendecinium can irritate an eroded inflamed canal. Do not add another cleaner or drop unless compatibility, spacing and tympanic safety are established; avoid traumatic cleaning.
  • Low systemic antibiotic concentrations can occur after routine topical otic treatment. Consider total aminoglycoside exposure, renal/neuromuscular vulnerability and concurrent ototoxic drugs when the canal is severely inflamed or treatment is repeated.
  • Shake to redisperse permitted slight sediment, avoid dropper contact/cross-ear contamination, label first opening, store below 25 °C protected from light and discard after 12 days. Wear gloves, wash hands and avoid eye/skin/mucosal contact or ingestion.
Assessment sources
  1. Otibiovin Czech SPC2011
  2. Otibiovin exact2026
  3. MSD otitis externa2026
  4. Topical otic review2016
  5. Otitis susceptibility2006
  6. Otomax VMD control2026
  7. Otomax FDA control2026
  8. Otic systemic exposure2012
  9. Pseudomonas review2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant treatment of severe feline external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management
5.7/10
Weak evidence support
vetman assessment

Otibiovin

triamcinolone acetonide 0.5 mg + salicylic acid 5 mg + gentamicin sulfate 2 mg + carbethopendecinium bromide 0.125 mg per ml, ear drops
Assessed clinical scopeCat · Label-concordant treatment of severe feline external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management · Into the ear
Care settingVeterinary otoscopy and cytology before cleaning, intact-tympanum confirmation, susceptibility-led selection for severe/recurrent infection, instructed high-frequency home treatment and planned clinical/cytological recheck
vetman score 5.7/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

Authorised for cats, but direct feline outcomes are absent and the high-frequency gentamicin/steroid regimen has important diagnostic, ototoxicity, spectrum and handling constraints; reserve for well-supported susceptible cases.

Regulatory and scientific credibility7.5/10

The exact dog/cat formulation, dose, strict indication restriction and 12-day open life are transparent, with current Georgian and Czech/EU authorisation. The regulator document is old and no independent exact-product trial or broad pharmacovigilance record was identified.

Clinical efficacy5.0/10

The exact label includes cats and mixed-species susceptibility data support possible activity, but no independent feline Otibiovin outcome study was identified. Feline causes differ, gentamicin coverage is incomplete and the formula lacks a conventional dedicated antifungal.

Safety and tolerability5.5/10

An intact tympanum materially reduces risk, and the exact label reports no known adverse effects, but topical gentamicin remains potentially ototoxic. Steroid masking/immunosuppression, irritation from salicylic acid/ethanol/antiseptic, low systemic antibiotic exposure and a painful diseased canal require active monitoring.

Clinical practicality4.0/10

The same high-frequency schedule is particularly burdensome in many cats and can increase restraint stress, missed doses and dropper contamination. Feline-friendly handling, pain control, demonstration and an early recheck are central to feasibility.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Hard stop: confirm an intact tympanic membrane before use. Do not use with rupture or when middle-ear exposure cannot be responsibly excluded. Gentamicin may be ototoxic, especially beyond an abnormal tympanum.
  • Obtain cytology before cleaning and diagnose the primary cause. The exact label restricts use to serious infection supported by pathogen identification, susceptibility to the active and resistance to common antibiotics; do not use as an empirical all-purpose ear drop.
  • Dose is 4–5 drops into the affected external canal 3–4 times daily initially, then 2–3 times daily after three days; massage gently. Usual duration is 5–7 days and the absolute label maximum is 12 days.
  • Recheck clinically and cytologically. Stop and urgently assess new hearing loss, head tilt, nystagmus, ataxia, vertigo, facial-nerve change, marked pain or worsening discharge; investigate otitis media rather than continuing blindly.
  • Gentamicin susceptibility is not universal and historical Pseudomonas coverage was about 85%. Culture/susceptibility is especially important for rods, severe/recurrent disease, prior antimicrobial exposure or poor response; minimise resistance selection.
  • No conventional dedicated antifungal or acaricide is present. Treat confirmed yeast/fungal disease and Otodectes with an appropriate effective plan; in-vitro gentamicin inhibition of Malassezia is not clinical antifungal equivalence.
  • Triamcinolone can reduce inflammation and pain but can mask progression, delay healing, promote secondary infection and cause local/systemic glucocorticoid effects. Do not extend beyond 12 days or repeat courses without re-diagnosis.
  • Salicylic acid, ethanol and carbethopendecinium can irritate an eroded inflamed canal. Do not add another cleaner or drop unless compatibility, spacing and tympanic safety are established; avoid traumatic cleaning.
  • Direct feline Otibiovin outcome evidence was not identified. Use feline-friendly restraint and analgesia, demonstrate dosing and reassess early; repeated forced treatment can make the high-frequency course impractical and unsafe.
  • Shake to redisperse permitted slight sediment, avoid dropper contact/cross-ear contamination, label first opening, store below 25 °C protected from light and discard after 12 days. Wear gloves, wash hands and avoid eye/skin/mucosal contact or ingestion.
Assessment sources
  1. Otibiovin Czech SPC2011
  2. Otibiovin exact2026
  3. MSD otitis externa2026
  4. Topical otic review2016
  5. Otitis susceptibility2006
  6. Feline otitis review2013
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Triamcinolone0.5 mg/ml Salicylic acid5 mg/ml Gentamicin2 mg/ml Carbethopendecinium bromide0.125 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოტიბიოვინი
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ 96/131/96-C
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Dogs/cats: after otoscopy, cytology, cleaning and intact-tympanum confirmation, instil 4–5 drops 3–4 times daily initially, then 2–3 times daily after three days; usually 5–7 days, maximum 12. Use only for a diagnosed susceptible serious infection under the exact label restriction. Treat the primary cause and recheck clinically/cytologically.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗